#160517

CS-5d Bcr-Abl and Btk small molecule kinase inhibitors

Cat. #160517

CS-5d Bcr-Abl and Btk small molecule kinase inhibitors

Cat. #: 160517

Sub-type: Inhibitor

Availability: Please enquire for quantities and pricing

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Cristian Salas

Institute: Pontificia Universidad Catolica de Chile

Tool Details
Handling
Target Details
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Tool name: CS-5d Bcr-Abl and Btk small molecule kinase inhibitors
  • Cancer: Blood cancer
  • Cancers detailed: Leukemia
  • Research fields: Cancer
  • Molecular formula: C26H28F2N8
  • Tool sub type: Inhibitor
  • Primary target: Bcr-Abl and Btk kinases
  • Description: This compound inhibits in nanomolar scale for Bcr-Abl (40 nM) and sub-micromolar scale for Btk kinases (0,58 M), both are related to the genesis and progression of myeloid and lymphoid leukaemia, respectively
  • Purpose: Inhibitor
  • Iupac: 9-(Cyclopropylmethyl)-N6-(3,4-difluorophenyl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-9H-purine-2,6-diamine
  • Molecular weight: 490.5509
  • Solubility: DMSO

Handling

  • Purity: 490.5509 g/mol
  • Storage conditions: Away from UV light
  • Shipping conditions: Dry Ice

Target Details

  • Primary target: Bcr-Abl and Btk kinases

Related Tools

  • Related tools: CS-5c Bcr-Abl and Btk small molecule kinase inhibitors

References

  • Bertrand et al. 2020. Bioorg Chem. 94:103361. PMID: 31699386.